News

AllSci has opened its Development Partner Program to R&D-driven life science organizations seeking to leverage the power of its revolutionary AI platform.

Systech, part of Markem-Imaje and Dover and a leading provider of digital identification and traceability software solutions, today announced the introduction

Stuart Therapeutics, Inc. a clinical-stage drug platform company developing novel therapies for ophthalmic diseases, today announced last patient

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible

Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic

InflaRx N.V. a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances

Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody Drug Conjugates (ADCs) with breakthrough potential, proudly announces the clearance of its Investigational New Drug application

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced

Partner Therapeutics, Inc. (PTx) today announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services to fund a phase 2 study